telisotuzumab vedotin (ABBV-399) - AbbVie
ANT-045 - Antikor Biopharma
https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!abstractdetails/0000965560
 
M. Deonarain1; G. Yahioglu2; B. Edwards3; I. Stamati4; S. Diez-Posada5; A. Pomowski3; L. Bouche4; L. Davies5; S. Ness3; I. Perez-Castro2; H. Desmond4
 
Sep 8, 2024
 
Next